Non-Small Cell Lung Cancer (NSCLC)

>

Latest News

FLAURA/FLAURA2 Regimens as Treatment Options for NSCLC
FLAURA/FLAURA2 Regimens as Treatment Options for NSCLC

January 2nd 2025

The discussion on NSCLC narrowed in on findings out of recent clinical trials, particularly involving a combination regimen of osimertinib and chemotherapy.

Afatinib/Osimertinib Treatment Combinations in EGFR-Mutated Advanced NSCLC
Afatinib/Osimertinib Treatment Combinations in EGFR-Mutated Advanced NSCLC

December 31st 2024

Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC
Longer Follow-Up Data Maintain Lasting Responses With Amivantamab/ Lazertinib in EGFR-Mutant NSCLC

December 28th 2024

Identifying HER2 Mutations for T-DXd Use in NSCLC
Identifying HER2 Mutations for T-DXd Use in NSCLC

December 27th 2024

Osimertinib Vs Amivantamab Combos in EGFR/TP53-Mutated NSCLC
Osimertinib Vs Amivantamab Combos in EGFR/TP53-Mutated NSCLC

December 25th 2024

More News